Filing Flows › Comparisons › ABCL vs IDYA
AbCellera Biologics vs Ideaya Biosciences: ABCL and IDYA compared
AbCellera Biologics is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $10.2M for Ideaya Biosciences (Q3 2026). AbCellera Biologics is growing faster (+19% against -95% a year earlier).
Where the money goes: ABCL and IDYA
AbCellera Biologics (ABCL) · Q3 2026
AbCellera Biologics, Q3 2026: revenue $10.6M (+19% year over year), operating margin -501.1%, net loss $40.8M, operating cash flow $26.9M. The chart follows the revenue to costs, profit and cash.
Ideaya Biosciences (IDYA) · Q3 2026
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
| AbCellera Biologics (ABCL) | Ideaya Biosciences (IDYA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.6M | $10.2M |
| Revenue growth, Y/Y | +19% | -95% |
| Operating margin | -501.1% | n/m |
| Net earnings | −$40.8M | −$126M |
| Net margin | -383.1% | — |
| Operating cash flow | $26.9M | −$93.5M |
| Free cash flow | $25.3M | — |
| Market value | $3.8B | $3.7B |
| Analysts’ mean target | $17.17 | $51.08 |
Where the revenue comes from
AbCellera Biologics
- Research fees: $10.5M (99%)
- Licensing and royalty revenue: $90K (1%)
Questions
Which is bigger, AbCellera Biologics or Ideaya Biosciences?
AbCellera Biologics is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $10.2M for Ideaya Biosciences (Q3 2026).
Is AbCellera Biologics or Ideaya Biosciences growing faster?
AbCellera Biologics is growing faster (+19% against -95% a year earlier).
More: AbCellera Biologics earnings · how AbCellera Biologics makes money · Ideaya Biosciences earnings · how Ideaya Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.